Balloon cell malignant melanoma

Summary

Balloon cell malignant melanoma (MONDO:0000929) is a cancer. A subtype of cutaneous melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	balloon cell malignant melanoma
Mondo ID	MONDO:0000929
DOID	DOID:10044
NCIT	C4227
SNOMED CT	403922007
UMLS	C0334426
MedGen	90780
Is cancer (heuristic)	yes

Also known as: balloon cell cutaneous (skin) melanoma · balloon cell malignant melanoma of skin · balloon cell malignant melanoma of the skin · balloon cell malignant skin melanoma · balloon cell melanoma · balloon cell skin melanoma

Disease family

This is a subtype of cutaneous melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › skin cancer › cutaneous melanoma › balloon cell malignant melanoma

Related subtypes (9): eyelid melanoma, nodular malignant melanoma, acral lentiginous melanoma, amelanotic skin melanoma, superficial spreading melanoma, lentigo maligna melanoma, desmoplastic melanoma, spitzoid melanoma, melanoma in congenital melanocytic nevus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.